Biotech Buys
Celltech�s little deal is big news.
The final cash deal in May that decided control of Oxford GlycoSciences (OGS), a biotech firm based in the United Kingdom, was on the small side—only about $170 million from Oxford�s London neighbor, the Celltech Group. But the fact that this deal happened at all, and that at least five companies fought hard to acquire the tiny genomics-proteomics-biopharmaceutical hybrid, makes it notable.
 |
 |
News Analysis
Ready or Not
Vive la Differentiation!
Shrinking Staffs
Double Attack
Bull�s-Eye?
» Biotech Buys
Sniffing for SNPs
|